Totality of evidence refutes neoplasm risk with fezolinetant - Authors' reply

Lancet. 2024 May 18;403(10440):1988. doi: 10.1016/S0140-6736(24)00708-6.
No abstract available

Publication types

  • Letter

MeSH terms

  • Heterocyclic Compounds, 2-Ring* / adverse effects
  • Humans
  • Neoplasms* / chemically induced
  • Neoplasms* / epidemiology
  • Thiadiazoles* / adverse effects

Substances

  • fezolinetant
  • Heterocyclic Compounds, 2-Ring
  • Thiadiazoles